HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

In Brief

This article was originally published in The Rose Sheet

Executive Summary

In a Q&A posted to FDA’s website, new CFSAN Director Susan Mayne says she’s “trying to learn, as rapidly as I can, everything I can about the safety of foods and cosmetics.” More news in brief.

You may also be interested in...



WEN Attorneys Meet With Top FDA Officials In ‘Continued Cooperation’

CFSAN Director Susan Mayne and other high-level FDA officials met with Guthy-Renker and WEN leadership and outside attorneys in September. The substance of the meeting is being kept under wraps, but it shows FDA’s continued involvement in the WEN issue, which drove discussion at the recent Senate HELP Committee hearing on cosmetics.

Germany's OTC Market in 2019: Stagnation Overall, Online Growth Continues

A weak cough and cold season in Germany last winter held back OTC sales growth in 2019, according to IQVIA, while the country's online pharmacy channel continued to expand. 

Stockwatch: Choppy Waters For Teva And Bausch

After most of the big pharmaceutical companies reported their full-year 2019 financial results, the second month of earnings season brings the long tail of smaller biotech companies and the generic pharmaceutical companies. There is more than one uncomfortable parallel from the former in the reports of the latter.

 

 

Related Companies

UsernamePublicRestriction

Register

RS019754

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel